| Literature DB >> 29596311 |
Jéssica S Giolo1, Juliene G Costa2, Jair P da Cunha-Junior3, Ana Cláudia A M Pajuaba4, Ernesto A Taketomi5, Adriele V de Souza6, Douglas C Caixeta7, Leonardo G Peixoto8, Erick P de Oliveira9, Sarah Everman10, Foued S Espindola11, Guilherme M Puga12.
Abstract
This study tested the effect of isoflavone supplementation in addition to combined exercise training on plasma lipid levels, inflammatory markers and oxidative stress in postmenopausal women. Thirty-two healthy and non-obese postmenopausal women without hormone therapy were randomly assigned to exercise + placebo (PLA; n = 15) or exercise + isoflavone supplementation (ISO; n = 17) groups. They performed 30 sessions of combined exercises (aerobic plus resistance) over ten weeks and consumed 100 mg of isoflavone supplementation or placebo. Blood samples were collected after an overnight fast to analyze the lipid profile, interleukin-6 (IL-6), interleukin-8 (IL-8), superoxide dismutase (SOD), total antioxidant capacity (FRAP), and thiobarbituric acid reactive substances (TBARS), before and after ten weeks of the intervention. There were no differences in the changes (pre vs. post) between groups for any of the inflammatory markers, oxidative stress markers or lipid profile variables. However, interleukin-8 was different between pre- and post-tests (p < 0.001) in both groups (&Delta; = 7.61 and 5.61 pg/mL) as were cholesterol levels (p < 0.05), with no interaction between groups. The combination of isoflavone supplementation and exercise training did not alter oxidative stress markers in postmenopausal women, but exercise training alone may increase IL-8 and decrease total cholesterol levels.Entities:
Keywords: aerobic and resistance exercises; anti-oxidant system; cytokines; menopause; soy protein
Mesh:
Substances:
Year: 2018 PMID: 29596311 PMCID: PMC5946209 DOI: 10.3390/nu10040424
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart with the distribution of the participants in the study.
Comparison of lipid profile, glucose, glycated hemoglobin and uric acid between the pre- and post-interventionin the placebo (PLA) and isoflavone (ISO) groups.
| Pre | Post | Δ |
|
|
| |
|---|---|---|---|---|---|---|
| Mean ± SE | Mean ± SE | (Groups) | (Moments) | (Groups * Moments) | ||
| Total Cholesterol (mg/dL) | ||||||
| PLA | 210 ± 8 | 197 ± 7 | −13.07 ± 3.72 | 0.34 | 0.04 | 0.07 |
| ISO | 215 ± 9 | 214 ± 9 | −1.13 ± 5.03 | |||
| LDL (mg/dL) | ||||||
| PLA | 126 ± 9 | 118 ± 6 | −7.54 ± 4.29 | 0.34 | 0.24 | 0.21 |
| ISO | 133 ± 8 | 133 ± 8 | 0.25 ± 4.21 | |||
| HDL (mg/dL) | ||||||
| PLA | 55.4 ± 3.6 | 50.5 ± 3.0 | −4.54 ± 1.27 | 0.25 | 0.07 | 0.16 |
| ISO | 58.1 ± 3.4 | 57.5 ± 2.6 | −0.59 ± 2.16 | |||
| VLDL (mg/dL) | ||||||
| PLA | 24.7 ± 3.1 | 23.5 ± 3.0 | −1.20 ± 1.60 | 0.77 | 0.91 | 0.47 |
| ISO | 22.7 ± 2.1 | 23.6 ± 2.0 | 0.88 ± 2.17 | |||
| Triglycerides (mg/dL) | ||||||
| PLA | 124 ± 16 | 118 ± 15 | −6.00 ± 7.98 | 0.77 | 0.91 | 0.47 |
| ISO | 113 ± 11 | 118 ± 10 | 4.38 ± 10.86 | |||
| Glucose (mg/dL) | ||||||
| PLA | 86.6 ± 1.7 | 86.8 ± 1.6 | 0.17 ± 1.33 | 0.92 | 0.27 | 0.20 |
| ISO | 87.5 ± 1.0 | 85.5 ± 1.4 | −2.08 ± 1.09 | |||
| Glycated Hemoglobin (%) | ||||||
| PLA | 5.50 ± 0.07 | 5.52 ± 0.10 | 0.02 ± 0.06 | 0.24 | 0.53 | 0.92 |
| ISO | 5.60 ± 0.05 | 5.63 ± 0.03 | 0.03 ± 0.05 | |||
| Uric Acid (mg/dL) | ||||||
| PLA | 4.5 ± 0.3 | 4.6 ± 0.3 | 0.04 ± 0.13 | 0.79 | 0.68 | 0.40 |
| ISO | 4.5 ± 0.2 | 4.4 ± 0.1 | −0.12 ± 0.14 | |||
PLA: placebo and exercise group; ISO: isoflavones and exercise group; LDL: Low density lipoprotein; HDL: High density lipoprotein; VLDL: Very low density lipoprotein.
Comparison of inflammatory and oxidative stress markers in the pre and post intervention moments in the placebo (PLA) and isoflavone (ISO) groups.
| Pre | Post | Δ |
|
|
| |
|---|---|---|---|---|---|---|
| Mean ± SE | Mean ± SE | (Groups) | (Moments) | (Groups * Moments) | ||
| Interleukin-8 (pg/mL) | ||||||
| PLA | 13.70 ± 1.91 | 21.31 ± 2.23 | 7.61 ± 2.50 | 0.92 | 0.001 | 0.55 |
| ISO | 14.52 ± 1.10 | 20.13 ± 1.79 | 5.61 ± 2.23 | |||
| Interleukin-6 (pg/mL) | ||||||
| PLA | 1.54 ± 0.39 | 1.30 ± 0.32 | −0.24 ± 0.27 | 0.76 | 0.22 | 0.98 |
| ISO | 1.42 ± 0.21 | 1.19 ± 0.26 | −0.23 ± 0.25 | |||
| FRAP (umol/L eq. Trolox) | ||||||
| PLA | 124.31 ± 5.24 | 123.18 ± 5.67 | −1.13 ± 3.48 | 0.65 | 0.39 | 0.73 |
| ISO | 122.47 ± 2.83 | 119.85 ± 3.03 | -2.63 ± 2.58 | |||
| TBARS (umol/L TBA-RS) | ||||||
| PLA | 24.65 ± 1.08 | 24.42 ± 1.17 | −0.23 ± 0.72 | 0.72 | 0.38 | 0.70 |
| ISO | 24.40 ± 0.61 | 23.82 ± 0.66 | −0.58 ± 0.56 | |||
| SOD (SOD/mg prot) | ||||||
| PLA | 0.190 ± 0.007 | 0.194 ± 0.008 | 0.003 ± 0.010 | 0.20 | 0.24 | 0.50 |
| ISO | 0.176 ± 0.007 | 0.193 ± 0.008 | 0.012 ± 0.008 | |||
PLA: placebo and exercise group; ISO: isoflavones and exercise group; FRAP: plasma ferric reduction capacity; TBARS: thiobarbituric acid reactive substances; SOD: superoxide dismutase.